ValiRx PLC VAL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 3.25
- Day Range
- GBX 3.20–3.28
- 52-Week Range
- GBX 3.20–15.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 430.13 Mil
- Volume/Avg
- 63,583 / 732,151
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.valirx.com
Valuation
|
Metric
|
VAL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.06 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VAL
|
|---|---|
Quick Ratio | 13.37 |
Current Ratio | 13.37 |
Interest Coverage | −577.05 |
Quick Ratio
VAL
Profitability
|
Metric
|
VAL
|
|---|---|
Return on Assets (Normalized) | −59.49% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −62.10% |
Return on Assets
VAL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lnvtdnfky | Xvm | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dvbxrkhw | Snjlvqw | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Llhdsbxv | Clqkqsc | $103.7 Bil | |
MRNA
| Moderna Inc | Dnwbjwqms | Fkktw | $47.9 Bil | |
ARGX
| argenx SE ADR | Vgzgwclk | Zfdd | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Zthcfxvxt | Zsrz | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rnfhplcd | Zkgmxp | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qcrkvhrff | Pxhhdz | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jgcgtpwhp | Bhrcwzj | $12.8 Bil | |
INCY
| Incyte Corp | Cfzkhfkjl | Gzwwm | $12.1 Bil |